SciTegic Announces Expanded Commitment to Pipeline Pilot at Unilever;

    Business Editors

    SAN DIEGO--(BUSINESS WIRE)--March 3, 2005--SciTegic, Inc., a wholly owned subsidiary of Accelrys, Inc. (NASDAQ: ACCL), today announced the sale of a multi-year license of Pipeline Pilot software to Unilever. SciTegic's data pipelining platform is now deployed at four Unilever sites across Europe and the U.S. Unilever is using Pipeline Pilot widely, primarily for informatics analyses and molecular modeling of compounds for their HPC (Home and Personal Care), Foods and safety, health and environmental R&D areas.
    Pipeline Pilot facilitates the integration of research data from multiple sources and in diverse formats. Its graphical interface provides an intuitive environment for analyses involving many different software tools and algorithms to be linked together and automated. Companies like Unilever are a good example of how Pipeline Pilot's revolutionary approach to data processing and analysis is being adopted by non-pharmaceutical companies to heighten the impact of their research.
    "The ease of use and modular nature of Pipeline Pilot has helped us reduce the time necessary to complete internal informatics activities by as much as 90%," said Jerry Winter, Head of Informatics for Unilever HPC R&D at Port Sunlight. "In addition, SciTegic's predictive modeling technologies provide us with better results than any dedicated data modeling package we have tried."
    "It is tremendously gratifying to see the deployment of Pipeline Pilot expanding rapidly inside key accounts like Unilever," said Dr. Mathew Hahn, VP and General Manager of SciTegic. "Our growing relationship with Unilever has proven invaluable and our products have benefited from the feedback resulting from its application to Unilever's unique business needs."

    About SciTegic

    SciTegic, a wholly owned subsidiary of Accelrys, Inc. (NASDAQ: ACCL), develops and markets informatics software for various industries, including the pharmaceutical and biotechnology industries. The company is pioneering a technology approach called "Data Pipelining" to process drug discovery data with unprecedented flexibility. This methodology is fast establishing its utility by accelerating informatics research for thousands of users at over one hundred customer sites worldwide. Further information about SciTegic is available at: www.scitegic.com.

    This press release contains forward-looking statements for purposes of the Private Securities Litigation Act of 1995 ("the Act"). When used anywhere in this document, the words expects, believes, anticipates, estimates, and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements herein include statements regarding the impact of the Pipeline Pilot on reducing research project timelines and the continued growth of the relationship with Unilever. Accelrys and SciTegic have based these forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the pace of customers' conversions to subscription style contracts, the successful implementation of Accelrys' strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of existing and potential future patent issues, additional competition, changes in economic conditions, and other risks described in Accelrys' filings with the Securities and Exchange Commission, including its most recent report on Form 10-Q. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Accelrys claims the protection of the safe-harbor for forward -looking statements in the Act, and disclaims any intent or obligation to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

--30--TJJ/la*

CONTACT: Accelrys Ian Clements, 858-799-5440 iclements@accelrys.com or SciTegic Marty Kleine, 858-279-8800 x214 mkleine@scitegic.com

KEYWORD: CALIFORNIA INTERNATIONAL EUROPE INDUSTRY KEYWORD: PHARMACEUTICAL BIOTECHNOLOGY SOFTWARE SOURCE: Accelrys

Copyright Business Wire 2005